Laurus Labs Past Earnings Performance
Past criteria checks 2/6
Laurus Labs hat die Erträge mit einer durchschnittlichen jährlichen Rate von 19.9% gesteigert, während die Branche Pharmaceuticals die Erträge growing mit 14.8% jährlich steigerte. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 18.8% pro Jahr gestiegen. Laurus Labs Die Eigenkapitalrendite des Unternehmens beträgt 4.8%, und die Nettomargen liegen bei 3.8%.
Key information
19.9%
Earnings growth rate
19.8%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 18.8% |
Return on equity | 4.8% |
Net Margin | 3.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Laurus Labs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jan 27Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?
Dec 01Laurus Labs (NSE:LAURUSLABS) Is Paying Out Less In Dividends Than Last Year
Oct 22These 4 Measures Indicate That Laurus Labs (NSE:LAURUSLABS) Is Using Debt Reasonably Well
Jul 06Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Dividend Of ₹1.20
Apr 30Is Laurus Labs (NSE:LAURUSLABS) A Risky Investment?
Dec 18Is Laurus Labs Limited (NSE:LAURUSLABS) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 27Is Laurus Labs (NSE:LAURUSLABS) Using Too Much Debt?
Sep 09Laurus Labs (NSE:LAURUSLABS) Has A Somewhat Strained Balance Sheet
Jun 11Laurus Labs (NSE:LAURUSLABS) Is Paying Out A Larger Dividend Than Last Year
May 02Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Feb 26With EPS Growth And More, Laurus Labs (NSE:LAURUSLABS) Is Interesting
Feb 11Does Laurus Labs (NSE:LAURUSLABS) Have A Healthy Balance Sheet?
Nov 26Laurus Labs (NSE:LAURUSLABS) Is Due To Pay A Dividend Of ₹0.80
Nov 13I Ran A Stock Scan For Earnings Growth And Laurus Labs (NSE:LAURUSLABS) Passed With Ease
Nov 12Laurus Labs (NSE:LAURUSLABS) Has Affirmed Its Dividend Of ₹0.80
Oct 30A Look At The Intrinsic Value Of Laurus Labs Limited (NSE:LAURUSLABS)
Oct 05Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?
Aug 10Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Jul 23Is Laurus Labs Limited (NSE:LAURUSLABS) Worth ₹547 Based On Its Intrinsic Value?
Jun 06We Think That There Are Issues Underlying Laurus Labs' (NSE:LAURUSLABS) Earnings
May 06Should You Be Adding Laurus Labs (NSE:LAURUSLABS) To Your Watchlist Today?
May 05We Think Laurus Labs (NSE:LAURUSLABS) Can Stay On Top Of Its Debt
Mar 16Could The Laurus Labs Limited (NSE:LAURUSLABS) Ownership Structure Tell Us Something Useful?
Mar 01Shareholders Are Raving About How The Laurus Labs (NSE:LAURUSLABS) Share Price Increased 331%
Feb 16There's A Lot To Like About Laurus Labs' (NSE:LAURUSLABS) Upcoming ₹0.40 Dividend
Feb 03Laurus Labs Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jan 30How Is Laurus Labs' (NSE:LAURUSLABS) CEO Compensated?
Jan 24Do Laurus Labs's (NSE:LAURUSLABS) Earnings Warrant Your Attention?
Jan 09Revenue & Expenses BreakdownBeta
How Laurus Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 49,821 | 1,879 | 6,320 | 0 |
30 Sep 23 | 53,320 | 3,678 | 6,244 | 0 |
30 Jun 23 | 56,834 | 5,637 | 6,074 | 0 |
31 Mar 23 | 60,406 | 7,901 | 5,995 | 0 |
31 Dec 22 | 60,845 | 9,176 | 5,786 | 0 |
30 Sep 22 | 55,684 | 8,683 | 5,532 | 0 |
30 Jun 22 | 51,960 | 8,374 | 5,291 | 0 |
31 Mar 22 | 49,356 | 8,275 | 5,043 | 0 |
31 Dec 21 | 49,227 | 8,937 | 4,899 | 0 |
30 Sep 21 | 51,823 | 10,128 | 4,685 | 0 |
30 Jun 21 | 51,177 | 10,532 | 4,537 | 0 |
31 Mar 21 | 48,135 | 9,836 | 4,380 | 0 |
31 Dec 20 | 42,407 | 7,971 | 4,190 | 0 |
30 Sep 20 | 36,819 | 5,977 | 4,068 | 0 |
30 Jun 20 | 32,555 | 4,120 | 3,866 | 0 |
31 Mar 20 | 28,317 | 2,553 | 3,554 | 0 |
31 Dec 19 | 26,277 | 1,883 | 3,452 | 0 |
30 Sep 19 | 24,276 | 1,326 | 3,257 | 0 |
30 Jun 19 | 23,035 | 923 | 3,112 | 0 |
31 Mar 19 | 22,919 | 938 | 3,037 | 0 |
31 Dec 18 | 22,170 | 957 | 2,942 | 0 |
30 Sep 18 | 21,665 | 1,127 | 2,901 | 0 |
30 Jun 18 | 21,168 | 1,453 | 2,800 | 0 |
31 Mar 18 | 20,562 | 1,676 | 2,699 | 0 |
31 Dec 17 | 19,687 | 1,917 | 2,870 | 0 |
30 Sep 17 | 19,954 | 2,019 | 2,772 | 0 |
30 Jun 17 | 19,733 | 2,014 | 2,673 | 0 |
31 Mar 17 | 19,046 | 1,881 | 2,349 | 0 |
31 Mar 16 | 17,776 | 1,337 | 1,983 | 0 |
31 Mar 15 | 13,266 | 684 | 1,748 | 0 |
31 Mar 14 | 11,597 | 972 | 1,473 | 0 |
Qualität der Erträge: LAURUSLABS hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: LAURUSLABSDie aktuellen Gewinnspannen (3.8%) sind niedriger als im letzten Jahr (15.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Ergebnisentwicklung: LAURUSLABSIn den letzten 5 Jahren sind die Gewinne von 19.9% jährlich gestiegen.
Beschleunigtes Wachstum: LAURUSLABSDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.
Erträge im Vergleich zur Industrie: LAURUSLABS hatte im vergangenen Jahr ein negatives Gewinnwachstum (-79.5%), was einen Vergleich mit dem Branchendurchschnitt Pharmaceuticals (23.5%) erschwert.
Return on Equity
Hohe Eigenkapitalrendite: LAURUSLABSDie Eigenkapitalrendite des Unternehmens (4.8%) wird als niedrig angesehen.